年轻BRCA1/2携带者早期乳腺癌的放疗管理:国际队列研究
该回顾性多中心国际队列纳入≤40岁、确诊侵袭性乳腺癌且携带胚系BRCA1/2致病变异的女性,比较保乳手术联合放疗(BCS+RT)、单纯乳房切除(MS)及乳房切除联合放疗(MS+RT)的生存与复发结局。中位随访8.2年,BCS+RT与MS alone的总生存无差异,但BCS+RT与更高的第二原发乳腺癌事件风险相关。
要点
- BCS+RT与MS alone的总生存无显著差异(aHR 1.02,95%CI 0.78-1.34)。
- BCS+RT与MS alone的无乳腺癌间期(BCFI)相当。
- BCS+RT较MS alone的第二原发乳腺癌事件风险更高(aHR 1.33,95%CI 1.07-1.66)。
核心结论
- 在年轻BRCA1/2携带者中,BCS+RT与MS alone相比总生存无差异,但第二原发乳腺癌事件风险更高。
- 第二原发乳腺癌事件的差异需谨慎解读,因组间BRCA检测时机和治疗年代存在差异。
- 数据支持在多学科框架内进行个体化局部区域管理。
研究设计与样本
- BRCA BCY Collaboration(NCT03673306)为回顾性、多中心队列研究。
- 纳入2000至2020年间治疗的≤40岁、侵袭性乳腺癌且确诊胚系BRCA1/2变异的女性。
- 共纳入4,837例患者:BCS+RT 1,704例(35.2%),MS alone 1,488例(30.8%),MS+RT 1,645例(34.0%)。
- 采用多变量Cox模型分析OS和BCFI,竞争风险模型分析IBR/CBC,并校正预设预后因素。
- 按BRCA基因、分期和肿瘤分级进行亚组分析。
主要发现
- 中位随访8.2年(IQR 4.8-12.7),BCS+RT与MS alone的OS无差异(aHR 1.02,95%CI 0.78-1.34)。
- BCFI在各组间相当。
- BCS+RT较MS alone的第二原发乳腺癌事件风险更高(aHR 1.33,95%CI 1.07-1.66),尤其在BRCA1变异和III期患者中。
关键数值与推荐
- OS:BCS+RT vs MS alone的aHR 1.02(95%CI 0.78-1.34)。
- 第二原发乳腺癌事件:BCS+RT vs MS alone的aHR 1.33(95%CI 1.07-1.66)。
临床怎么用
- 对年轻BRCA1/2携带者早期乳腺癌,BCS+RT可作为不劣于MS alone的总生存选择。
- 需告知BCS+RT与第二原发乳腺癌事件风险升高相关,尤其BRCA1变异和III期患者。
- 局部区域治疗决策应在多学科框架内个体化制定。
局限性
- 回顾性设计,组间BRCA检测时机和治疗年代存在差异。
- 第二原发乳腺癌事件差异需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The oncological safety of breast-conserving surgery followed by radiation therapy (BCS + RT) in young women carrying pathogenic or likely pathogenic BRCA1/2 variants remains debated, with mastectomy (MS) often favoured despite limited comparative real-world evidence. We evaluated survival and recurrence outcomes associated with different loco-regional strategies in a large international cohort of young BRCA carriers. METHODS: The BRCA BCY Collaboration (NCT03673306) is a retrospective, multicentre cohort including women aged ≤ 40 years with invasive breast cancer and confirmed germline BRCA1/2 variants treated between 2000 and 2020. Outcomes were compared between patients treated with BCS + RT, MS alone, or MS plus RT (MS + RT). Endpoints were overall survival (OS), breast cancer-free interval (BCFI), and second primary breast cancer events, defined as ipsilateral breast recurrence (IBR) or contralateral breast cancer (CBC). Multivariable Cox models were used for OS and BCFI. Competing-risks models were used for IBR/CBC. Models were adjusted for prespecified prognostic factors, and subgroup analyses were conducted by BRCA gene, stage, and tumour grade. RESULTS: Among 4,837 patients, 1,704 (35.2%) received BCS + RT, 1,488 (30.8%) MS alone, and 1,645 (34.0%) MS + RT. After a median follow-up of 8.2 years (IQR 4.8-12.7), OS did not differ between BCS + RT and MS alone (adjusted hazard ratio [aHR] 1.02, 95% CI 0.78-1.34). BCFI was comparable across groups. BCS + RT was associated with a higher risk of second primary breast cancer events compared with MS alone (aHR 1.33, 95% CI 1.07-1.66), particularly in patients with BRCA1 variants and stage III disease. CONCLUSION: In young BRCA1/2 carriers, BCS + RT was not associated with worse OS compared with MS alone, despite a higher risk of second primary breast events. Differences in second primary breast cancer events should be interpreted cautiously given differences in BRCA testing timing and treatment era across groups. These data support individualised loco-regional management within a multidisciplinary framework.
引用
- Becherini C, Blondeaux E, Delucchi V, et al. Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study. Radiother Oncol. 2026. PMID: 41941938. doi:10.1016/j.radonc.2026.111523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。